Novo Nordisk did not immediately respond Pharmaceutical Technology’s request for comment. The request to the FDA is just the latest action Novo Nordisk has taken related to semaglutide compounding.

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining dose in short supply -- the lowest dose of Wegovy -- is now listed as available, CNN reported.

In July, the FDA warned healthcare providers of dosing errors associated with compounded versions of semaglutide, saying it received reports of hospitalizations and adverse events tied to the issue.

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...

Novo Nordisk shares dropped after REDEFINE-1 trial disappointment. Find out why NVO stock could still offer long-term growth despite the underperformance.

The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma ...

Novo Nordisk reups bid for high-dose Ozempic after March FDA snub It's crucial to help patients living with obesity understand that "it's not their fault, and that it's not just about eating less ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in ...